Animal Pharm is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. Please do not redistribute without permission.

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Investments

Set Alert for Investments

Latest From Investments

BioValence aims to take 'game changer' aqua candidate global

Malaysian company BioValence recently won the Innovation Award at the Aquaculture Innovation Summit 2017 in London for its RetroMAD1 antiviral protein. But what else has the company got planned for other candidates in its pipeline? Animal Pharm analyst Sian Lazell spoke to the firm to find out more.

Aquaculture R&D

Vietnam eyes domestic avian flu vaccine production

Southeast Asian country Vietnam will produce its own vaccines against two common strains of avian influenza, according to local media.

Asia Pacific Vietnam

French firm edges out doubters and gets closer to commercializing insects as aqua feed

Using insects as a nutritious and cost effective feed in aquaculture has not always been flavor of the month. Following regulatory changes the sector is now becoming a commercial reality. Animal Pharm analyst Malcolm Flanagan talks to Antoine Hubert, the chief executive of Ynsect, about the prospects for the firm and the nascent industry.

Europe France

ViroVet adds Capricorn Venture Partners to series A

Belgian company ViroVet has added another €1.5 million ($1.76 million) to its working capital after completing the second closing of its series A financing round.

Vaccines Pharmaceuticals

MWI invests in osteoarthritis product development

US veterinary distributor MWI Animal Health is to pump cash into a start-up specializing in treatment of arthritis and rheumatoid conditions in companion animals.

Investments Osteoarthritis

ZIVO algal platform holds potential for 'endless supply of bioactive compounds'

Phytogenics is a term increasingly cropping up on the radar of animal health, as more firms turn to R&D in natural products. Animal Pharm analyst Sian Lazell spoke to US firm ZIVO Bioscience about how it is using algae to develop a pipeline of bioactive product candidates. 

North America United States
See All
Advertisement
UsernamePublicRestriction

Register